Neos Therapeutics (NASDAQ: NEOS) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Neos Therapeutics and SCYNEXIS, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neos Therapeutics 0 1 4 0 2.80
SCYNEXIS 0 1 5 0 2.83

Neos Therapeutics presently has a consensus price target of $16.20, indicating a potential upside of 62.00%. SCYNEXIS has a consensus price target of $10.00, indicating a potential upside of 449.45%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Neos Therapeutics.

Insider & Institutional Ownership

45.7% of Neos Therapeutics shares are owned by institutional investors. Comparatively, 31.0% of SCYNEXIS shares are owned by institutional investors. 5.2% of Neos Therapeutics shares are owned by company insiders. Comparatively, 4.0% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neos Therapeutics and SCYNEXIS’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neos Therapeutics $9.15 million 31.69 -$83.33 million ($3.42) -2.92
SCYNEXIS $260,000.00 199.92 -$29.98 million ($0.81) -2.25

SCYNEXIS has lower revenue, but higher earnings than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neos Therapeutics and SCYNEXIS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neos Therapeutics -339.52% -551.26% -68.57%
SCYNEXIS -8,569.46% -64.12% -37.45%

Summary

SCYNEXIS beats Neos Therapeutics on 9 of the 13 factors compared between the two stocks.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

SCYNEXIS Company Profile

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.